Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer:phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis

Autor: S I, Labidi-Galy, M, Rodrigues, J L, Sandoval, J E, Kurtz, F, Heitz, A M, Mosconi, I, Romero, U, Denison, S, Nagao, I, Vergote, G, Parma, T J, Nøttrup, E, Rouleau, G, Garnier, A, El-Balat, C, Zamagni, C, Martín-Lorente, E, Pujade-Lauraine, A, Fiévet, I L, Ray-Coquard

Publikováno v: Labidi-Galy, S I, Rodrigues, M, Sandoval, J L, Kurtz, J E, Heitz, F, Mosconi, A M, Romero, I, Denison, U, Nagao, S, Vergote, I, Parma, G, Nøttrup, T J, Rouleau, E, Garnier, G, El-Balat, A, Zamagni, C, Martín-Lorente, C, Pujade-Lauraine, E, Fiévet, A & Ray-Coquard, I L 2023, ' Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer : phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis ', Annals of Oncology, vol. 34, no. 2, pp. 152-162 . https://doi.org/10.1016/j.annonc.2022.11.003

BACKGROUND: In the phase III PAOLA-1 study, the addition of maintenance olaparib to bevacizumab in patients with newly diagnosed high-grade ovarian cancer (HGOC) resulted in prolonged progression-free survival (PFS), particularly for homologous recom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7238bd7941a935684f35290251f1a332
https://curis.ku.dk/ws/files/338357926/1_s2.0_S0923753422047330_main.pdf

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

176O Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)

Autor: S. Nagao, P. Harter, A. Leary, C. Cropet, S. Pignata, K. Fujiwara, A.J. Gonzalez Martin, G. Bogner, I. Vergote, N. Colombo, J. Maenpaa, F. Selle, B. Schmalfeldt, G. Scambia, E.M. Guerra Alia, C. Lefeuvre-Plesse, A. Belau, A. Lortholary, M. Gropp-Meier, E. Pujade-Lauraine, I. Ray-Coquard

Publikováno v: Annals of Oncology. 33:S1503-S1504

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::48b230251ac6fac184a323da030cc7e9
https://doi.org/10.1016/j.annonc.2022.10.212

LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)

Autor: I.L. Ray-Coquard, A. Leary, S. Pignata, C. Cropet, A.J. Gonzalez Martin, G. Bogner, H. Yoshida, I.B. Vergote, N. Colombo, J. Maenpaa, F. Selle, B. Schmalfeldt, G. Scambia, E.M. Guerra Alia, C. Lefeuvre-Plesse, A. Belau, A. Lortholary, M. Gropp-Meier, E. Pujade-Lauraine, P. Harter

Publikováno v: Annals of Oncology. 33:S1396-S1397

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8ccde783d34eae474cd9272e7e33767b
https://doi.org/10.1016/j.annonc.2022.08.025